NCT05079282

Study of ONO-4685 in Patients With Relapsed or Refractory T Cell Lymphoma

An Open-label, Multi-center, Non-randomized Phase I Dose Escalation Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of ONO-4685 Given as Monotherapy in Patients With Relapsed or Refractory T Cell Lymphoma

• Status: Recruiting
• Phase: Phase 1
• Study type: Interventional
• Enrollment: 217 (estimated)
• Sponsor: Ono Pharmaceutical Co., Ltd. · Industry
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

This study will investigate the safety, tolerability, pharmacokinetics, and preliminary efficacy of ONO-4685 in patients with relapsed or refractory T cell Lymphoma

Conditions

• Relapsed or Refractory T Cell Lymphoma

Interventions

Type	Name	Description
DRUG	ONO-4685	ONO-4685 is administered by IV infusion. The administration of ONO-4685 will be continued until disease progression or unacceptable toxicity is observed

Timeline

• Start date: 2021-12-10
• Primary completion: 2027-08-31
• Completion: 2028-08-31
• First posted: 2021-10-15
• Last updated: 2026-02-13

Locations

20 sites across 1 country: United States

Regulatory

• FDA-regulated drug study